ORIC Pharmaceuticals Ownership | Who Owns ORIC Pharmaceuticals?
ORIC Pharmaceuticals Ownership Summary
ORIC Pharmaceuticals is owned by 20.90% institutional investors, 6.69% insiders, and 72.40% retail investors. Nextech invest is the largest institutional shareholder, holding 9.17% of ORIC shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.65% of its assets in ORIC Pharmaceuticals shares.
ORIC Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | ORIC Pharmaceuticals | 20.90% | 6.69% | 72.40% |
| Sector | Healthcare Stocks | 42.57% | 10.84% | 46.59% |
| Industry | Biotech Stocks | 45.28% | 10.77% | 43.95% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Nextech invest | 7.16M | 9.17% | $85.95M |
| Ecor1 capital | 6.73M | 8.61% | $80.74M |
| Vr adviser | 6.60M | 8.44% | $79.16M |
| Viking global investors lp | 6.57M | 8.41% | $78.87M |
| Nextech invest | 5.29M | 7.49% | $42.66M |
| Blackrock | 4.83M | 7.17% | $34.15M |
| Pfizer | 5.38M | 6.88% | $64.52M |
| Blackrock funding, inc. /de | 5.28M | 6.75% | $63.32M |
| Vanguard group | 4.65M | 5.95% | $55.80M |
| Sr one capital management, lp | 4.51M | 5.78% | $54.18M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Column group | 3.54M | 52.48% | $42.49M |
| Pfizer | 5.38M | 14.75% | $64.52M |
| Nextech invest | 7.16M | 13.08% | $85.95M |
| Invus financial advisors | 1.01M | 7.98% | $7.12M |
| Sr one capital management, lp | 4.51M | 7.84% | $54.18M |
| Nextech invest | 5.29M | 6.92% | $42.66M |
| Euclidean capital | 989.41K | 4.99% | $11.87M |
| Vr adviser | 6.60M | 4.46% | $79.16M |
| First turn management | 2.16M | 3.89% | $25.91M |
| Ecor1 capital | 6.73M | 3.87% | $80.74M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Ecor1 capital | 6.73M | 3.87% | 5.11M |
| Orbimed advisors | 3.64M | 1.03% | 2.74M |
| Blackrock | 4.83M | 0.00% | 1.65M |
| Vanguard group | 4.65M | 0.00% | 1.53M |
| Royce & associates lp | 1.46M | 0.17% | 1.22M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Commodore capital lp | - | - | -2.00M |
| Avidity partners management lp | - | - | -1.27M |
| Frazier life sciences management | - | - | -1.07M |
| Ally bridge group (ny) | - | - | -485.63K |
| Schonfeld strategic advisors | - | - | -426.90K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Polar capital | 468.61K | 0.03% | 468.61K | $5.62M |
| Driehaus capital management | 148.78K | 0.01% | 148.78K | $1.79M |
| Exome asset management | 120.64K | 0.88% | 120.64K | $1.45M |
| Boothbay fund management | 110.83K | 0.02% | 110.83K | $1.33M |
| Caption management | 49.39K | 0.00% | 49.39K | $592.67K |
Sold Out
| Holder | Change |
|---|---|
| Capital performance advisors llp | -1.00 |
| Clearstead advisors | -4.00 |
| Nelson, van denburg & campbell wealth management group | -8.00 |
| True wealth design | -26.00 |
| Coldstream capital management | -45.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | 52 | -62.04% | 16,331,312 | -82.02% | 20 | 0.15% | 33 | -54.17% | 13 | -74.00% |
| Jun 30, 2025 | 143 | -0.69% | 93,335,020 | 17.83% | 119 | 0.96% | 75 | -8.54% | 52 | 36.84% |
| Mar 31, 2025 | 11 | -91.91% | 11,102,130 | -85.35% | 15 | 0.14% | 8 | -89.87% | 2 | -92.86% |
| Dec 31, 2024 | 39 | -68.29% | 10,134,721 | -85.49% | 14 | 0.15% | 26 | -58.06% | 7 | -81.58% |
| Sep 30, 2024 | 123 | 10.81% | 69,828,652 | 3.33% | 98 | 0.98% | 62 | -16.22% | 38 | 100.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard US Total Market Shares ETF | 1.88M | 2.65% | - |
| ACAP Strategic A | 2.23M | 2.29% | 244.72K |
| Vanguard Total Stock Mkt Idx Inv | 1.90M | 2.20% | -42.04K |
| Fidelity Growth Compy Commingled Pl O | 1.28M | 1.81% | - |
| Fidelity Growth Compy Commingled Pl S | 1.31M | 1.35% | 1.34K |
| iShares Russell 2000 ETF | 1.10M | 1.13% | - |
| US Small-Cap Growth II Equity Comp | 914.12K | 1.07% | 914.12K |
| Eventide Healthcare & Life Sciences I | 951.43K | 0.98% | 951.43K |
| T. Rowe Price Health Sciences | 925.93K | 0.95% | -102.51K |
| Fidelity Advisor Biotechnology I | 581.72K | 0.82% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jan 16, 2026 | Heyman Richard A. | - | Sell | $42.02K |
| Jan 16, 2026 | Heyman Richard A. | - | Sell | $38.41K |
| Dec 16, 2025 | Multani Pratik S | Chief Medical Officer | Sell | $97.13K |
| Dec 16, 2025 | Piscitelli Dominic | Chief Financial Officer | Sell | $97.13K |
| Dec 16, 2025 | Chacko Jacob | PRESIDENT AND CEO | Sell | $302.37K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q4 | - | 6 |
| 2025 Q3 | - | 3 |
| 2025 Q2 | 2 | 9 |
| 2025 Q1 | - | - |
| 2024 Q4 | - | 3 |
ORIC Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools